Cite
HARVARD Citation
Emmett, L. et al. (2021). ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU international. pp. 642-651. [Online].